This content is only available within our institutional offering.
11 May 2020
LIBERUM: Healthcare - First hurdle cleared and Novartis is still the standout
AstraZeneca PLC (AZN:LON), 12,010 | Bayer AG (BAYN:ETR), 0 | GSK plc (GSK:LON), 1,640 | Novartis AG (NOVN:SWX), 0 | Novo Nordisk A/S Class B (NOVO.B:CSE), 0 | Roche Holding Ltd Dividend Right Cert. (ROG:SWX), 0 | Sanofi (SAN:PAR), 0
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
LIBERUM: Healthcare - First hurdle cleared and Novartis is still the standout
AstraZeneca PLC (AZN:LON), 12,010 | Bayer AG (BAYN:ETR), 0 | GSK plc (GSK:LON), 1,640 | Novartis AG (NOVN:SWX), 0 | Novo Nordisk A/S Class B (NOVO.B:CSE), 0 | Roche Holding Ltd Dividend Right Cert. (ROG:SWX), 0 | Sanofi (SAN:PAR), 0
- Published:
11 May 2020 -
Author:
Graham Doyle | Alistair Campbell -
Pages:
73